Core Insights - Bonaccord Capital Partners has acquired a minority interest in Prime Finance, a leading commercial real estate credit platform, to support its growth and strategic initiatives [1][3] Company Overview - Prime Finance is recognized as a top 10 commercial real estate debt investor, known for its disciplined underwriting and consistent performance across market cycles [2] - The firm manages over $15 billion in assets as of December 31, 2025, and offers a diverse range of financing options across various commercial real estate sectors [9][10] Investment Details - Bonaccord's investment aims to strengthen Prime Finance's balance sheet, expand its credit platform, and enhance technology and data capabilities [3] - The partnership will not alter Prime Finance's day-to-day management or strategic direction [3] Strategic Goals - Prime Finance seeks to scale its differentiated real estate credit platform and expand product offerings for borrowers and investors [4] - Bonaccord focuses on making strategic minority investments in mid-market alternative asset managers, providing growth capital and support for scaling operations [4][6] Advisory and Legal Support - Goldman Sachs acted as the financial advisor for Prime Finance, while Simpson Thacher & Bartlett LLP and Sidley Austin LLP provided legal counsel to Prime Finance and Bonaccord, respectively [5]

Core Insights - Constellation Wealth Capital has made a minority investment in BIP Wealth, a $5.5 billion registered investment advisor (RIA), aimed at enhancing BIP's mergers and acquisitions (M&A) pipeline in the Southeast and beyond [1][2] - BIP Wealth's CEO, Bill Harris, emphasizes that the partnership will facilitate growth opportunities that will benefit clients and the team, highlighting Constellation's expertise in private investment and advanced planning [2] - Constellation, founded in 2023 by Karl Heckenberg, focuses on investing in wealth management firms and has previously invested in several firms, including the $20 billion Merit Financial [3] Company Overview - BIP Wealth, established in 2007, operates in multiple locations in Georgia and expanded to Nashville in 2022, having grown its assets under management by $725 million last year and expecting to exceed that total in 2026 [3][4] - The firm has also added approximately $1.2 billion through acquisitions of The Money Advisor Group and Prehmus Financial, with expectations that Constellation's investment will accelerate inorganic growth [4] - Constellation's strategy includes investing between $25 million and $200 million in wealth businesses with managed assets ranging from $1 billion to $200 billion [5]

Core Viewpoint - DaVita Inc. reported strong fourth-quarter earnings and provided optimistic guidance for fiscal 2026, leading to a significant increase in stock price [1]. Earnings Summary - Adjusted earnings were $3.40 per share, surpassing the consensus estimate of $3.16 [2]. - Sales reached $3.62 billion, reflecting a year-over-year increase of 5.8% and exceeding the consensus of $3.497 billion [2]. - Revenue per treatment increased from $410.59 to $422.60, driven by higher average reimbursement rates and seasonal factors [2]. Year-to-Date Changes - The year-to-date performance was influenced by the inclusion of phosphate binders in the ESRD Prospective Payment System and annual increases in average reimbursement rates, including Medicare [3]. - Total U.S. dialysis treatments for Q4 2025 were 7,264,520, averaging 91,608 treatments per day, which is a slight decrease of 0.1% from Q3 2025 [3]. Cost and Treatment Growth - Normalized non-acquired treatment growth for Q4 2025 compared to Q4 2024 was down by 0.6% [4]. - Patient care costs per treatment rose from $273.54 to $279.60, primarily due to increased health benefit expenses and medical supply costs [4]. Guidance - For fiscal 2026, DaVita anticipates adjusted earnings between $13.60 and $15.00 per share, exceeding the consensus of $12.65 [5]. - Adjusted operating income is expected to range from $2.09 billion to $2.24 billion, with treatment volume projected to remain flat compared to 2025 [5]. - Revenue per treatment is expected to grow by approximately 1% to 2%, while cost growth is anticipated to be between 1.25% and 2.25% [5]. Additional Investments - DaVita's CFO mentioned an estimated $40 million headwind from the expiration of enhanced premium tax credits, which is offset by the removal of a $45 million headwind from a previous cyber incident [6]. - DaVita is making a minority investment of approximately $200 million in Elara Caring, which is expected to positively impact other income lines [7]. Analyst View - Barclays has maintained an Equal-Weight rating on DaVita and raised the price target from $143 to $158 [8]. - Following the earnings report, DaVita's stock rose by 21.69% to $135.31 [8].